Nurse Practitioner Busted: DEA Yanks Her Pill-Prescribing Power
Published Date: 10/14/2026
Notice
Summary
Katherine Curtis, a nurse practitioner from Indiana, lost her DEA license to handle controlled substances because she no longer has state permission and allegedly wrote prescriptions that didn’t meet medical standards. This means she can’t legally prescribe or manage these drugs anymore, protecting public safety. The decision is final as she didn’t ask for a hearing within the required 30 days.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Katherine Curtis
Katherine Curtis, N.P., had her DEA Certificate of Registration No. MS5411765 revoked by a final Decision and Order published October 14, 2026. Because her Indiana APRN and controlled substance registration expired on October 31, 2025 and she admitted issuing improper controlled‑substance prescriptions from June 2024 to May 2025, she may no longer legally prescribe, dispense, or handle controlled substances under her DEA registration.
Patients Lose Access from This Prescriber
Because the DEA revoked Katherine Curtis's registration, she cannot legally provide controlled‑substance prescriptions to patients. The agency found she issued prescriptions outside the usual course of practice to six individuals between June 2024 and May 2025, and the revocation is described as protecting public safety.
15‑Day Window to Seek Reconsideration
The Order states that Katherine Curtis may file a properly supported motion for reconsideration of the Agency's factual finding (that she is not licensed to practice as an APRN or to handle controlled substances in Indiana) within fifteen calendar days of the date of the Order; such motions and responses must be filed and served by email to the DEA Office of the Administrator at [email protected].
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20942, Schedules of Controlled Substances: Temporary Placement of MGM-15 and MGM-16 in Schedule I
The DEA is keeping two substances, MGM-15 and MGM-16, temporarily listed as Schedule I drugs, meaning they’re treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or possesses these substances, with strict rules and penalties in place. The current order stays active until a new one replaces it, so the controls continue without interruption.
2026-20943, Schedules of Controlled Substances: Temporary Placement of 7- Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I
The DEA plans to temporarily put 7-hydroxymitragynine and mitragynine pseudoindoxyl on Schedule I if their amounts go over a certain limit. This means some products with these substances will face strict rules, but smaller amounts might still be allowed. The change affects makers, sellers, and users, with new rules expected soon that could impact business and safety regulations.
Previous / Next Documents
Previous: 2026-20936, RTW Biotech Growth Fund and RTW Investments, LP
RTW Biotech Growth Fund and RTW Investments, LP want permission to offer different types of shares, charge fees for early withdrawals, and add ongoing service fees. This affects investors in these funds by potentially changing how they pay fees and access their money. The SEC will decide by November 2, 2026, unless someone asks for a hearing, so keep an eye on deadlines!
Next: 2026-20938, Guidance to U.S. Customs and Border Protection Regarding the Assessment of “U.S. Content” for Purposes of Implementing Tariffs Pursuant to Clause (2)(D) of Proclamation 11032 of June 1, 2026
Starting October 14, 2026, U.S. Customs will use new rules to figure out how much of a product from Canada or Mexico is made in the U.S. This helps decide if special tariffs on aluminum, steel, and copper apply. If your business deals with these metals, expect changes in how tariffs are calculated, which could affect costs and imports.